TY - JOUR
T1 - Characteristics and outcomes of patients with multiple myeloma aged 21–40 years versus 41–60 years
T2 - a multi-institutional case-control study
AU - Jurczyszyn, Artur
AU - Nahi, Hareth
AU - Avivi, Irit
AU - Gozzetti, Alessandro
AU - Niesvizky, Ruben
AU - Yadlapati, Sujitha
AU - Jayabalan, David S.
AU - Robak, Paweł
AU - Pika, Tomas
AU - Andersen, Kristian T.
AU - Rasche, Leo
AU - Mądry, Krzysztof
AU - Woszczyk, Dariusz
AU - Raźny, Małgorzata
AU - Usnarska-Zubkiewicz, Lidia
AU - Knopińska-Posłuszny, Wanda
AU - Wojciechowska, Małgorzata
AU - Guzicka-Kazimierczak, Renata
AU - Joks, Monika
AU - Grosicki, Sebastian
AU - Ciepłuch, Hanna
AU - Rymko, Marcin
AU - Vesole, David H.
AU - Castillo, Jorge J.
N1 - Publisher Copyright:
© 2016 John Wiley & Sons Ltd
PY - 2016/12/1
Y1 - 2016/12/1
N2 - We compared the outcomes of multiple myeloma (MM) patients aged 21–40 and 41–60 years in the novel agent era. This case-control study included 1089 patients between 2000 and 2015. Cases and controls were matched for sex, International Staging System (ISS) stage and institution. There were 173 patients in the younger group and 916 patients in the older group. Younger patients presented with a higher incidence of lytic lesions (82% vs. 72%; P = 0·04) and high-risk cytogenetic abnormalities (83% vs. 68%; P = 0·007), but lower rate of elevated lactate dehydrogenase (21% vs. 44%; P < 0·001). Five- and 10-year overall survival (OS) in younger versus older patients was 83% vs. 67% and 56% vs. 39%, respectively (P < 0·001). Similar results were seen when studying the subset of 780 patients who underwent autologous transplantation. Younger patients with ISS stage 1 had a better OS than older patients (P < 0·001). There was no survival difference between younger and older patients with ISS stage 2 or 3. Younger MM patients, aged 21–40 years, treated in the era of novel agents have a better OS than their counterparts aged 41–60 years, but the survival advantage observed in younger patients was lost in more advanced stages of MM.
AB - We compared the outcomes of multiple myeloma (MM) patients aged 21–40 and 41–60 years in the novel agent era. This case-control study included 1089 patients between 2000 and 2015. Cases and controls were matched for sex, International Staging System (ISS) stage and institution. There were 173 patients in the younger group and 916 patients in the older group. Younger patients presented with a higher incidence of lytic lesions (82% vs. 72%; P = 0·04) and high-risk cytogenetic abnormalities (83% vs. 68%; P = 0·007), but lower rate of elevated lactate dehydrogenase (21% vs. 44%; P < 0·001). Five- and 10-year overall survival (OS) in younger versus older patients was 83% vs. 67% and 56% vs. 39%, respectively (P < 0·001). Similar results were seen when studying the subset of 780 patients who underwent autologous transplantation. Younger patients with ISS stage 1 had a better OS than older patients (P < 0·001). There was no survival difference between younger and older patients with ISS stage 2 or 3. Younger MM patients, aged 21–40 years, treated in the era of novel agents have a better OS than their counterparts aged 41–60 years, but the survival advantage observed in younger patients was lost in more advanced stages of MM.
KW - myeloma
KW - outcomes
KW - survival
KW - transplantation
KW - young
UR - https://www.scopus.com/pages/publications/84996636528
U2 - 10.1111/bjh.14328
DO - 10.1111/bjh.14328
M3 - Article
C2 - 27682187
AN - SCOPUS:84996636528
SN - 0007-1048
VL - 175
SP - 884
EP - 891
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 5
ER -